>> Data Safety Monitoring Committee overseeing the trial has reported no serious safety concerns and recommends that the trial proceed. Myriad believes that the Phase II study in more than 200 patients with mild to moderate Alzheimer's disease will be completed in the clinic on schedule during the first calendar quarter of 2005. <<
Shorts here are lazy, perhaps insane. Period. The logic is established, from Golde's lab. The trial has "green light" from DSMB. There are three cancer-projects (MPC-6827, MPI-176716 and MPC-4505) headed for IND to back flurbie, and the predictive medicine business is perfectly positioned for the future of pharma-FDA interaction. There's two years of burn in the bank with no debt, the existing business is of decent margin, Prolexys is gonna rock, prostate is a second (and, IMO, justified) shot on goal for flurbie, the market cap is tiny compared to peers, and we've got geniuses like Webber and Hines on the wrong side.
It doesn't get any better. I hope. |
